#2469 - Brigham Buhler

We roll in loose today—stuffed noses and all—because allergies are hammering us; Austin’s cedar hits different, and it’s got me sounding like I slept in a hay bale.

You do sound plugged up; mine flare too, and colostrum actually helps when I take it consistently.

Cedar wrecked me when I moved from Houston, then my body adjusted; little things like that get overlooked, just like what’s happening with peptides.

Quick update: after years of filing unanswered FOIA requests and getting stonewalled, I finally have a seat at the table and real optimism that peptides will be reclassified; this leadership is open to evidence instead of old dogma.

It helps that people in charge actually use these tools and have seen benefits; millions of folks feel better on peptides.

I’m one of them; I was obese and prediabetic in my 30s, trusted an assembly‑line system, and learned it wasn’t built for prevention—now the same openness that’s fixing peptide policy is reshaping hormone therapy too.

Can you walk through testosterone and the fear of prostate cancer? That’s what stops a lot of guys.

That fear traces to a tiny 1930s report where taking a man from zero testosterone toward normal briefly raised a theoretical risk; modern data shows no causal link, and once receptors are saturated, optimal levels appear protective rather than harmful.

So what did that old report actually conclude, and who was at risk?

It tied a precursor hormone rise to concern in a chemically castrated patient; subsequent real‑world use—millions on TRT—never produced a spike in prostate cancer, which tracks with today’s prevalence.

How did a shaky idea live this long?

Medicine confuses consensus with truth; old teaching gets repeated, and it spreads like urban legend, which is exactly what’s happening in the peptide debate as people demand billion‑dollar trials for cash‑pay tools clinics already use safely at scale.

By the way, GLP‑1s are peptides too; they’re everywhere now, and you can see it on faces all over Hollywood.

Clinicians prescribe off‑label every day, so saying peptides “lack evidence” while using off‑label meds is a double standard.

We saw that tension during COVID when cheap off‑label options clashed with expensive approved drugs.

The GLP‑1 boom triggered lobbying fire; big pharma framed compounders as patent pirates, ignoring that shortages prompted compounding in the first place and that many molecules start with taxpayer‑funded research; now reclassifying as biologics could prolong exclusivity, which sets a bad precedent.

No wonder regulators are overwhelmed; getting up to speed on this is brutal.

Lobbying buys long meetings and scary numbers, yet the FDA’s own track record shows lots of post‑approval label changes; people now question blanket claims, and natural short‑chain peptides are tough to patent, which explains some of the friction.

If only drug companies made peptides, they’d be pricier but splashed across TV with beach‑jogging ads.

Exactly; it would explode overnight as a business.

I see three tracks: the insurance‑driven sick‑care machine, luxury concierge care few can afford, and pill‑mill telehealth chasing volume; my aim is affordable, high‑touch prevention that pairs AI with real clinicians and tracks wins with wearables, DEXA, and VO2 instead of living off prescriptions.

You’re actually trying to help people, but public companies must chase quarterly profits; that incentive warps care.

We’ll scale slower to stay high‑quality; AI is a tool, not the relationship, and shortcuts backfire—look at the ad that pushed a branded GLP‑1 name for a compounded product, sparked a crackdown, then turned into an exclusive pharma deal; it felt engineered.

Even if that gets exposed, it’ll barely make a ripple.

The danger is regulators punish the whole sector while the instigator prospers; better to build a parallel, cash‑pay life raft that respects doctor–patient autonomy and lets someone with a serious condition act now, not in ten years.

Most will still use the old system anyway, but pharma wants every dollar, not a fair split.

Their patents paid off; let compounders serve patient‑specific needs like micro‑dosing, allergies, and shortages, especially with 503A pharmacies when 503B bulk is shut.

So how do you fix the black‑market mess where people buy mystery vials online?

Right now is the real Wild West—most fills are gray or black market, often misdosed and shipped without guidance; restore clinician‑led compounding with verified ingredients and inspections, and you slash risk overnight.

That sounds reasonable, but pharma prefers a world where only they win.

States are moving faster—Texas, Florida, Utah, and Arizona are building right‑to‑try and stem‑cell pathways; with sane checks, you get access, safety, and medical tourism while the feds catch up.

People are flying to Panama and Tijuana for stem cells and coming back better; why can’t they do it here?

I’m confident Texas will widen access and attract patients, the same way food policy reforms spread from states upward.

We spend the most and stay the sickest; how long do we defend a model with constant label changes and well‑known harms?

It’s not a comic‑book conspiracy; it’s a captive system shaped by special interests that leaves us unfit and overmedicated, so we need a preventive cash lane next to it.

Preventive care beats stacking scripts and managing side effects forever.

Cash‑pay prevention is accountable because patients fire you if it doesn’t work; they can fill anywhere, while PBMs steer people inside insurance—our goal is measurable wins, large datasets, and pattern‑spotting by genes and response, not pill counts.

You’re also layering in genetics; explain that piece.

Our app will streamline refills and add an AI assistant, then full gene sequencing alongside DEXA, VO2, and wearables so we can personalize care; your genes are the software, and knowing them changes the plan.

Are other countries already pushing gene edits, and what happens when you crank up bone density—do you sink?

Some places are testing switches that boost bone or muscle; denser bones can make you less buoyant, and beyond that we share longevity pathways with creatures like Greenland sharks, so mapping and safely modulating those genes could open a new era.

Are these traits innate or trained?

The blueprint is inherited, and epigenetics decides what shows up; sequencing explains gifts and weak spots so we can tailor care today while we work toward precise, temporary gene modulation tomorrow—like flipping the right switch for a set period.

Genes tilt the odds, they don’t lock your fate, so you change habits to blunt risk; the future points to flipping traits on and off rather than resigning to them.

Take LRP5: one variant can affect eye vessels and bone, with outcomes from strong skeletons to vision loss, which is wild.

The most shocking thing I’ve seen is MUSE stem cells; we flew to Japan ready to debunk them, sat with Mari and pored over a decade of data, and left thinking this could rewrite regenerative care.

MUSE means multilineage, stress‑enduring; Mari noticed a tiny, odd stem-cell subset that survived an accidental overnight in the lab, and that fluke kicked off everything.

Conventional MSCs are very safe but mostly coach healing; they don’t turn into new tissue, whereas MUSE appear pluripotent without tumor behavior in studies.

Think of MUSE like kids with open futures that can grow into tendon, bone, or neuron; they even ‘eat’ a damaged cell and adopt its code, returning as a fresher version.

Safety looks outstanding so far with no flu‑like reactions reported, and their immune calming is strong enough to transiently protect foreign tissue in animal models, much like pregnancy’s tolerance window.

Clinically, they’re already helping fat graft acceptance in plastic surgery and can be delivered intranasally to the brain, where signals linger in the midbrain for a long stretch.

They also home to damage better than typical MSCs, slip past the lungs, and act within days.

Could we just switch on our own MUSE instead of adding cells?

Levels crater with age and are scarce in diabetics, which may explain slow healing; early work even showed one IV bag nudging mitochondrial age back by about a year and a half.

Overseas reports are striking, from a comatose patient showing brain responsiveness after treatment to newborn encephalitis cases normalizing when dosed, plus encouraging heart and neuro data.

As research stacks up, gene tools and MUSE will likely converge and amplify each other.

Some teams want to pre‑teach MUSE to become a target cell before infusion; the stress‑enduring trait even makes room‑temperature shipping possible, but we still need measured optimism and a clear federal path.

Expect pushback where entrenched drug dollars are on the line.

That’s why compassionate access matters when safety is strong and patents are thin; intranasal MUSE lighting up the midbrain for months hints at real shots on Parkinson’s and dementia.

It’s maddening that people must fly abroad while loved ones here could benefit now.

We also added plasmapheresis in Austin, a decades‑old therapy that filters inflammatory junk from plasma and replaces albumin, then we stack MSCs, peptides, and other supports like a body oil change.

That can help clear endocrine disruptors like BPA and phthalates from ultra‑processed packaging.

A quick example: Philip Franklin Lee had sky‑high microplastics and rock‑bottom testosterone; after ditching plastics and running our protocol, his levels rebounded without testosterone therapy, though stacked treatments make it hard to credit a single lever, so we’re working to isolate effects better.

Thank you for pushing this forward; this is exciting, practical, and exactly what people need to hear.

Appreciate you; your platform helped open doors with regulators, and we’re doing our best to guide sensible access so more people can benefit—more to come.